Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-726-2 | CAS number: -
No experimental in vivo or in vitro data on oral, inhalation and dermal absorption, distribution, metabolism and excretion are available for the target substance Di-C12-18 alkyldimethyl ammonium chloride. However, toxicokinetic data are available for Cetrimonium Bromide and DDAC. A justification for read-across is attached to IUCLID section 13.The toxicokinetic assessment is partially based on physicochemical properties.
In a toxicokinetic study, female rats received a single oral gavage administration of 0.8 mg/kg [1-14C] Cetrimonium Bromide in water. After 3 days 92% of the dose was excreted in feces and about 1% in urine. About 85% of the radioactive substance excreted in feces after 3 d was the parent compound. About 2% of the administrated radioactivity was excreted in the bile during the first 12 hours after treatment. Taken together, these data indicate that about 10% of the administered dose was absorbed. Only small amounts of radioactivity were found in the blood and organs. Highest peak concentratons (at 4-8 h) were found in liver (about 0.8% of administered radioactivity) and lower levels in kidneys, spleen, heart, lung and skeletal muscle.
In a toxicokinetic study, rats received a single oral gavage dose of 14C-labelled DDAC. The majority (>90%) of the administered dose was excreted via the faeces. From the amount excreted in urine (<3%) and tissue residues (<1%), the report authors concluded that the oral absorption was less than 10%.
The physicochemical properties of the target and source substances are at least partially favourable for absorption (molecular weight < 500 g/mol,but weighted mean calculated log Kow >4). The longer chain di- and trialkyl compounds are probably absorbed to a lesser extent. The substances are quaternised, which is disadvantageous for the diffusion across the biological membranes in the gastro-intestinal tract. In general, solids with a microscale particle diameter are too large to be directly taken up by pinocytosis and have to be dissolved before they can be absorbed. The target and source substances have a similarly low water solubility, which is likely to reduce absorption.
Based on the available experimental data and on physicochemical properties, a low bioavailability after oral administration can be assumed. For chemical safety assessment, a value of 10% is considered appropriate.
Both source substances and the target substances are solid at room temperature and have a low vapour pressure (<1E-05 Pa) therefore substance evaporation and uptake by inhalation as vapour is for all of them unlikely.
The extent of inhalation absorption deduced from the physico-chemical properties and from the results of oral absorption studies are expected to be low. Furthermore, the target substance Di-C12-18 alkyldimethyl ammonium chlorideas well as the source substances are quaternised ammonium compounds, and the inhalation absorption of ionic substances is generally low. For chemical safety assessment, a value of 20% is considered appropriate.
The physicochemical properties of the target and source substances are at least partially favourable for absorption (molecular weight < 500 g/mol,but weighted mean calculated log Kow >4). Taking into account the ionic nature of the substances (quaternary ammonium ions) a high dermal absorption is nevertheless unlikely. For chemical safety assessment, a value of 10% is considered appropriate.
As small molecules a wide distribution can be expected. No information on potential target organs is available. However, as ionised molecules, the source and target substances are thought to not readily diffuse across biological membranes.
In a study with orally administered didecyldimethyl ammonium chloride in rat, the majority (>90%) of the dose was excreted very likely unabsorbed via the faeces. From the amount excreted in urine (<3%) and tissue residues (<1%), the report authors concluded that the oral absorption was <10%.Metabolism, which may be by microbial activity, comprised the oxidation of the two decyl side chains to form hydroxy and hydroxyketo derivatives; metabolism of methyl side chains was not found. No cleavage of the side chains (beta-oxidation) was reported.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again